# Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

> **NCT01081938** · PHASE4 · TERMINATED · sponsor: **Sanofi** · enrollment: 15 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** INSULIN GLARGINE
- **DRUG:** INSULIN GLULISINE

## Key facts

- **NCT ID:** NCT01081938
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Recruitment challenges
- **Last updated:** 2012-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081938, "Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01081938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*